CSL (OTCMKTS:CSLLY) Shares Gap Down – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price gapped down prior to trading on Friday . The stock had previously closed at $64.25, but opened at $61.11. CSL shares last traded at $65.2275, with a volume of 113,073 shares traded.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CSLLY shares. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research report on Monday, December 29th. Canaccord Genuity Group upgraded shares of CSL from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. Finally, Royal Bank Of Canada raised CSL from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, CSL currently has an average rating of “Buy”.

CSL Stock Performance

The company’s 50 day moving average price is $59.93 and its two-hundred day moving average price is $66.60. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 2.46.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.